Navigation Links
Alemtuzumab in Medical News

Genzyme and Bayer Schering Pharma AG, Germany to Present New Data on Alemtuzumab in Multiple Sclerosis at ECTRIMS

CAMBRIDGE, Mass. and BERLIN /PRNewswire-FirstCall/ -- Genzyme Corporation and Bayer Schering Pharma AG, Germany announce that important, new clinical data will be presented this weekend from two studies regarding alemtuzumab use in patients with multiple sclerosis (MS) at the 23rd Congress of ...

Launch of Highly Anticipated Oral Agents and Increasing Use of Current and Emerging Injectable Drugs Will Drive the Multiple Sclerosis Drug Market to Nearly $10 Billion in 2018

...s. The report also finds that three additional emerging agents - Biogen Idec's pegylated interferon-beta-1a, Genzyme/Bayer Schering/Bayer HealthCare's alemtuzumab (currently marketed as Campath/MabCampath) and BioMS Medical/Eli Lilly's dirucotide - will also contribute substantially to market growth by providing...

GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer

...wed limited or no response to both fludarabine and alemtuzumab treatment (fludarabine alemtuzumab refractory) and patients who were refractory to fl...rabine and considered inappropriate candidates for alemtuzumab due to bulky tumor masses (>5 cm) in their lymp...

Researchers find predictive tests and early treatment delay progression of blood cell cancer

...rimental treatments if appropriate. The two targeted therapies studied, alemtuzumab and rituximab, are widely used in advanced-stage CLL. Both are monoclonal a...treatment with chemotherapy and monoclonal antibodies such as rituximab and alemtuzumab can be prescribed, but these treatments do not cure the disease. Researc...

Cell-Mediated Immunity and Anti-HLA Antibody Tests Provide Insight to Immune Response in Renal Transplant Patients

... Donaldson J, Basu A, et al. 411 Living donor kidney transplants using alemtuzumab pre-conditioning and tacrolimus monotherapy: 5 year experience. Abstra...Rejection characteristics of 200 living donor kidney transplants using alemtuzumab induction and tacrolimus monotherapy: 3 year follow-up. Abstract no. 2...

Multiple Independent Studies Report on Use of Cylex's Immune Cell Function Assay in Postoperative Monitoring of Kidney, Liver, and Heart Transplant Recipients

...D. -- "411 living donor kidney transplants using alemtuzumab pre-conditioning and tacrolismus monotherapy: ... date) of living kidney donor transplants with alemtuzumab preconditioning, including the role of the Cyl... of 200 living donor kidney transplants using alemtuzumab induction and tacrolismus monotherapy" (H. P. Tan,...

Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year

...erixafor) for stem-cell transplantation and alemtuzumab for multiple sclerosis. Fourth-Quarter 2007 High... clinical trials-particularly the phase 3 study of alemtuzumab for multiple sclerosis; and (3) product launch...l pipeline. The product will join Mozobil and alemtuzumab at the forefront of a development portfolio with ...
Alemtuzumab in Medical Technology

Living Donor Kidney Transplants Using Alemtuzumab Pre-Conditioning and Tacrolimus Monotherapy: Long-Term Safety and Efficacy

The results of these studies will be presented during the American Transplant Congress in Boston , MA May 30 - June 3, 2009 COLUMBIA, Md., May 31 /PRNewswire/ -- The results of two large studies presented by researchers from the Starzl Transplant Institute at the University of P...

Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis

Three-Year Analysis Demonstrates Robust, Highly Statistically Significant Treatment Effect of Alemtuzumab Compared to Rebif(R) CAMBRIDGE, Mass., Oct. 15 /PRNewswire-FirstCall/ -- Genzyme Corporation (Nasdaq: GENZ ) today announced that top-line, three-year data from a completed Phase ...

Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis

CAMBRIDGE, Mass., and BERLIN, Sept. 26 /PRNewswire-FirstCall/ -- Genzyme Corporation (Nasdaq: GENZ ) and Bayer Schering Pharma AG, Germany today announced that the first patient has been treated in the first of two planned Phase 3 trials examining the safety and efficacy of alemtuzumab for th...

Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL

...ed a combination of cyclophosphamide, fludarabine, alemtuzumab (Campath) and rituximab (CFAR) as a frontline ther...e of B-Cell Chronic Lymphocytic Leukemia Following alemtuzumab Therapy: Retrospective Study within Various Cytoge...points. Abstract #329 Subcutaneous alemtuzumab (Campath) in Fludarabine-Refractory CLL: Final Res...

Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)

...r no response (refractory) to both fludarabine and alemtuzumab treatment (double refractory; DR), and patients wh...rabine and considered inappropriate candidates for alemtuzumab due to bulky tumor masses in their lymph nodes (bu...nts whose disease is refractory to fludarabine and alemtuzumab treatment or patients who are refractory to fludar...

Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology

.... PST) -- Clinical Outcome of B-Cell Chronic Lymphocytic Leukemia Following alemtuzumab Therapy: Retrospective Study Within Various Cytogenetic Risk Categories ... Poster 329 (December 8, 12:00 p.m. PST) -- Subcutaneous alemtuzumab (Campath) in Fludarabine-Refractory CLL: Final Results of the CLL2H Trial o...

Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study

...rabine and considered inappropriate candidates for alemtuzumab due to bulky tumor in their lymph nodes. An object...ne and alemtuzumab. In the fludarabine refractory, alemtuzumab inappropriate patient group, an objective response...atients who are refractory to both fludarabine and alemtuzumab and patients who are refractory to fludarabine who...

Prospective Microbial Analysis of Bronchoalveolar Lavage Fluids with Immune Function Testing Can Distinguish Between Fungal Colonization and Fungal Disease In Lung Transplant Recipients

...nalysis, while also being prospectively monitored and classified for episodes of infection according to standardized criteria. All patients received alemtuzumab induction and tacrolimus suppression to prevent organ rejection. Results of ImmuKnow assays of CMI were included in the analysis if and when they were...

Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN

...ative study showed significant results in favor of alemtuzumab versus Rebif CAMBRIDGE, Mass. and WAYNE, N.J., Ma... Dr. Coles' presentation showed patients taking alemtuzumab at the high dose experienced an 87 percent reducti...eated with Rebif. At the low dose, patients taking alemtuzumab experienced similar results, with a 72 percent red...
Alemtuzumab in Biological Technology

Genmab A/S: Ofatumumab Pivotal CLL Data to be Presented at ASH

...:45AM PST - Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An International Pivotal Trial. Poster I-682 - Complement (C) ...

Genzyme Reports Strong Second-Quarter Growth

... -- Genzyme continued to enroll patients in two ongoing Phase 3 trials of alemtuzumab for the treatment of multiple sclerosis. Final, three-year efficacy and safety data from the Phase 2 trial comparing alemtuzumab with Rebif(R) (interferon beta-1a) for the treatment of relapsing-remitting...

Genzyme Reports Strong First-Quarter Growth

...nical trials-particularly the phase 3 study of alemtuzumab for multiple sclerosis. This estimate also re...st data package from Genzyme sponsored studies. alemtuzumab for multiple sclerosis -- Final, three-year effi...d safety data from the Phase 2 trial comparing alemtuzumab with Rebif (interferon beta-1a) for the treatment ...

Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study

...atients who are refractory to both fludarabine and alemtuzumab and 66 fludarabine refractory patients who are considered inappropriate candidates for alemtuzumab due to bulky tumor in their lymph nodes. An interi...atients who are refractory to both fludarabine and alemtuzumab and patients who are refractory to fludarabine who...
Other Tags
(Date:7/27/2015)... ... ... Dr. Robert G. Schwartz , principal of Greenville, SC-based Piedmont Physical ... Centers in order to offer his patients a new system of care utilizing laser ... , Peripheral neuropathy is a disease caused by damage to the peripheral nerves, and ...
(Date:7/27/2015)... ... 28, 2015 , ... Conducting Advanced Root Cause Analysis CAPA ... Quality of Investigations , **Presented by FDAnews and Learning Plus**, Sept. 16-17, 2015 ... the #1 reason for 483 observations since 1997! , The FDA's enforcement plan ...
(Date:7/27/2015)... ... ... The National Association of Professional Women (NAPW) honors Deana ... Circle. She is recognized with this prestigious distinction for leadership in healthcare. With more ... networking organization exclusively for professional women. , “I’m pleased to recognize Deana with this ...
(Date:7/27/2015)... ... July 28, 2015 , ... ... Baum- Lappe as a 2015 Professional Woman of the Year. Ms. Baum-Lappe ... most-recognized networking organization of professional women in the country, spanning virtually every industry ...
(Date:7/27/2015)... Falls Church, VA (PRWEB) , ... July 27, ... ... Quality and Compliance From Step One, **FDAnews Webinar**, Aug. 13, 2015 — 1:30 ... operating procedures are one of the first things FDA investigators will look at ...
Breaking Medicine News(10 mins):Health News:Piedmont Physical Medicine & Rehabilitation, P.A. Partners with Realief® Neuropathy Centers to Offer Peripheral Neuropathy Laser Treatment 2Health News:FDAnews Announces: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 16-17, 2015, Raleigh, NC 2Health News:FDAnews Announces: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 16-17, 2015, Raleigh, NC 3Health News:FDAnews Announces: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 16-17, 2015, Raleigh, NC 4Health News:NAPW Inducts Deana Skidmore, Assistant Director of Nursing at Wilton Meadows Rehablilitation and Health Care Center, Into its VIP Woman of the Year Circle 2Health News:NAPW Inducts Gilda Baum-Lappe, Journalist / Correspondent of Hollywood Foreign Press Association Into its VIP Woman of the Year Circle 2Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 2Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 3Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 4
(Date:7/23/2015)... , July 23, 2015 Research and ... of the "Global Outlook of the Biometrics ... The global biometrics market is ... and commercial applications owing to the uptake of ... a transformation that enhances the growth of biometrics ...
(Date:7/13/2015)... , July 13, 2015 Synaptics ... of human interface solutions, today announced sampling of ... and display driver integration (TDDI) product targeting smartphones ... first to combine Synaptics , best-in-class touch ... display driver technology developed in the company,s Japan ...
(Date:7/9/2015)... July 9, 2015  Synaptics Inc. (NASDAQ: ... human interface solutions, today announced a new ... fully hardware encapsulated fingerprint sensor and matching ... is literally off the grid, isolating fingerprint ... within the fingerprint sensor to provide ultimate ...
Breaking Biology News(10 mins):Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3
Other Contents